RSV vaccines for babies too expensive at current prices, Hiqa warns 

A pilot vaccine programme running for the last two winters has seen a collapse in RSV numbers among babies. However Hiqa has now advised future costs could range from €15.6m to €58.5m over five years depending on the type of immunisation used. File picture

The RSV vaccines used for babies are too expensive at current prices even though they are “safe and effective”, Hiqa has told the health minister.

Costs need to be almost halved before they would be cost-effective, the regulator will tell Jennifer Carroll MacNeill and the HSE today in its final report.